Table 1.
Patient characteristics
| Patient characteristic | Result |
| Median age (years) | 74 (range, 60–85) |
| 6 patients, 60–65 years | |
| 35 patients, 65–79 years | |
| 8 patients, ≥80 years | |
| Male/Female (n) | 34/19 |
| AML rising from AHD (n) | 13 |
| t-AML (N) | 6 |
| Median presenting WBC count, ×103/μL | 2.7 (range, 0.4–150.0) |
| Median BM blasts,% | 52 (range, 20–92%) |
| Cytogenetics (n) | |
| CBF | 1, patient had t(8;21)(q22;q22),,−7 |
| Normal karyotype | 21 |
| Complex karyotype | 16 (12 with ≥5 abnormalities) |
| Other | 13 |
| MRC* prognostic risk score, percent of patients | |
| Good | 19 |
| Standard | 32 |
| Poor | 49 |
AHD, antecedent hematologic disorder; BM, bone marrow; CBF, core binding factor; n, number of patients; t-AML, therapy-related AML.
*See ref. 17.